Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Completed 17Active not recruiting 13Recruiting 5Terminated 2Withdrawn 1No longer available 1

Sponsor Class

OTHER 20INDUSTRY 5NETWORK 2OTHER_GOV 1FED 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 4Metastatic Castration-resistant Prostate Neoplasms 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × apalutamide × Clear all
NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT06095089 2026-06-05

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
355 enrolled
Genitourinary

Prostatic Neoplasms

NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT07406282 2026-04-09

Double-DARE

Bayer

Recruiting
1,400 enrolled
Genitourinary

Prostatic Neoplasms

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

ORIC Pharmaceuticals

Phase 1 Recruiting
250 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡